VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone

By Karen Roman

VERAXA Biotech AG (Nasdaq: VRXA) said it started cell line development for its lead BiTAC T-cell engager program, collaborating with ATUM to apply proprietary technology for stable clonal cell line generation.

"Today's news underscores our commitment to accelerate the development path of our growing BiTAC-TCE portfolio," said Christoph Erkel, Ph.D., VERAXA's Vice President Research and Development. "Initiating cell line development with ATUM is an important next step for our lead BiTAC-TCE program following the encouraging preclinical data we presented at AACR."

Register for our weekly newsletter HERE

READ MORE

VERAXA Biotech Expands R&D Hub in Heidelberg as Programs Advance Towards Clinical Development

Contact:

Exec Edge

[email protected]

Click HERE to follow us on LinkedIn

The post VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone appeared first on ExecEdge.

View Comments